The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis

Efthimios Dardiotis, Athina Maria Aloizou, Vasileios Siokas, George P. Patrinos, Georgia Deretzi, Panayiotis Mitsias, Michael Aschner, Aristidis Tsatsakis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that affects motor neurons and leads to death within 2 to 3 years after the first symptoms manifest. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in fundamental cellular processes and, post-transcriptionally, the translation levels of target mRNA transcripts. We searched PubMed for studies that examined miRNAs in ALS patients and attempted to group the results in order to find the strongest miRNA candidate for servings as an ALS biomarker. The studies on humans so far have been diverse, yielding considerably heterogeneous results, as they were performed on a wide variety of tissues and subjects. Among the miRNAs that were found consistently deregulated are miR-206, miR-133, miR-149, and miR-338-3p. Additively, the deregulation of some specific miRNAs seems to compose a miRNA expression profile that is specific for ALS. More research is required in order for the scientific community to reach a consensus.

Original languageEnglish (US)
JournalJournal of Molecular Neuroscience
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Amyotrophic Lateral Sclerosis
MicroRNAs
Small Untranslated RNA
Motor Neurons
PubMed
Neurodegenerative Diseases
Biomarkers
Gene Expression
Messenger RNA
Research

Keywords

  • Amyotrophic lateral sclerosis
  • Biomarker
  • Epigenetics
  • MicroRNA
  • Neurodegeneration

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Dardiotis, E., Aloizou, A. M., Siokas, V., Patrinos, G. P., Deretzi, G., Mitsias, P., ... Tsatsakis, A. (Accepted/In press). The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis. Journal of Molecular Neuroscience. https://doi.org/10.1007/s12031-018-1204-1

The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis. / Dardiotis, Efthimios; Aloizou, Athina Maria; Siokas, Vasileios; Patrinos, George P.; Deretzi, Georgia; Mitsias, Panayiotis; Aschner, Michael; Tsatsakis, Aristidis.

In: Journal of Molecular Neuroscience, 01.01.2018.

Research output: Contribution to journalArticle

Dardiotis, Efthimios ; Aloizou, Athina Maria ; Siokas, Vasileios ; Patrinos, George P. ; Deretzi, Georgia ; Mitsias, Panayiotis ; Aschner, Michael ; Tsatsakis, Aristidis. / The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis. In: Journal of Molecular Neuroscience. 2018.
@article{ee6f992e097640b58ab0153b81777366,
title = "The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis",
abstract = "Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that affects motor neurons and leads to death within 2 to 3 years after the first symptoms manifest. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in fundamental cellular processes and, post-transcriptionally, the translation levels of target mRNA transcripts. We searched PubMed for studies that examined miRNAs in ALS patients and attempted to group the results in order to find the strongest miRNA candidate for servings as an ALS biomarker. The studies on humans so far have been diverse, yielding considerably heterogeneous results, as they were performed on a wide variety of tissues and subjects. Among the miRNAs that were found consistently deregulated are miR-206, miR-133, miR-149, and miR-338-3p. Additively, the deregulation of some specific miRNAs seems to compose a miRNA expression profile that is specific for ALS. More research is required in order for the scientific community to reach a consensus.",
keywords = "Amyotrophic lateral sclerosis, Biomarker, Epigenetics, MicroRNA, Neurodegeneration",
author = "Efthimios Dardiotis and Aloizou, {Athina Maria} and Vasileios Siokas and Patrinos, {George P.} and Georgia Deretzi and Panayiotis Mitsias and Michael Aschner and Aristidis Tsatsakis",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12031-018-1204-1",
language = "English (US)",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",

}

TY - JOUR

T1 - The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis

AU - Dardiotis, Efthimios

AU - Aloizou, Athina Maria

AU - Siokas, Vasileios

AU - Patrinos, George P.

AU - Deretzi, Georgia

AU - Mitsias, Panayiotis

AU - Aschner, Michael

AU - Tsatsakis, Aristidis

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that affects motor neurons and leads to death within 2 to 3 years after the first symptoms manifest. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in fundamental cellular processes and, post-transcriptionally, the translation levels of target mRNA transcripts. We searched PubMed for studies that examined miRNAs in ALS patients and attempted to group the results in order to find the strongest miRNA candidate for servings as an ALS biomarker. The studies on humans so far have been diverse, yielding considerably heterogeneous results, as they were performed on a wide variety of tissues and subjects. Among the miRNAs that were found consistently deregulated are miR-206, miR-133, miR-149, and miR-338-3p. Additively, the deregulation of some specific miRNAs seems to compose a miRNA expression profile that is specific for ALS. More research is required in order for the scientific community to reach a consensus.

AB - Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that affects motor neurons and leads to death within 2 to 3 years after the first symptoms manifest. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in fundamental cellular processes and, post-transcriptionally, the translation levels of target mRNA transcripts. We searched PubMed for studies that examined miRNAs in ALS patients and attempted to group the results in order to find the strongest miRNA candidate for servings as an ALS biomarker. The studies on humans so far have been diverse, yielding considerably heterogeneous results, as they were performed on a wide variety of tissues and subjects. Among the miRNAs that were found consistently deregulated are miR-206, miR-133, miR-149, and miR-338-3p. Additively, the deregulation of some specific miRNAs seems to compose a miRNA expression profile that is specific for ALS. More research is required in order for the scientific community to reach a consensus.

KW - Amyotrophic lateral sclerosis

KW - Biomarker

KW - Epigenetics

KW - MicroRNA

KW - Neurodegeneration

UR - http://www.scopus.com/inward/record.url?scp=85056322066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056322066&partnerID=8YFLogxK

U2 - 10.1007/s12031-018-1204-1

DO - 10.1007/s12031-018-1204-1

M3 - Article

C2 - 30415446

AN - SCOPUS:85056322066

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

ER -